R3 Vascular
Mountain View
About R3 Vascular
R3 Vascular creates bioresorbable scaffold technology with a sirolimus coating for the treatment of peripheral arterial disease. R3 Vascular's polymer and proprietary technologies are used to create scaffolds that balance strength and flexibility for the treatment of peripheral arterial disease. The magnitude BRS device is the thinnest BRS ever tested in this clinical setting, with a strut thickness of 98 microns across its entire usable range of diameters.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $104.8M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2024)
- Website: r3vascular.com
Industries & Categories
Health Diagnostics, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/r3-vascular-60949 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.